Amy O’Shea and the last mile of a good idea

A good idea in agriculture has a demanding itinerary. It must leave the laboratory, survive manufacturing, find a distributor, reach a grower and justify the trouble of trying something new. There are plenty of opportunities to miss a connection. Amy O’Shea has spent her career working along that route, in jobs where an invention eventually has to become somebody’s purchase.

In April 2024, she became chief executive and a board director of Invaio Sciences, alongside a CEO-Partner appointment at Flagship Pioneering. The company was already developing biological approaches to crop protection. Her arrival brought a commercial operator into the next stage of its development: expanding the business and getting its technologies into agricultural use.

O’Shea’s stated ambition was to give growers more dependable, environmentally sustainable alternatives. Dependability is the useful word here. A grower must make decisions with money, land and a season at stake. An attractive explanation of how a product works can begin a conversation. Repeated usefulness has to carry the conversation further.

That makes her an interesting figure in a business often narrated through scientific discovery. Her career invites a closer look at the less theatrical work surrounding an invention: building teams, arranging production and understanding what customers will actually do. The distance between a promising experiment and a repeat order is where her story takes shape.

The degree that does not explain the résumé

O’Shea holds a bachelor’s degree in Classical Civilizations from Boston University and an MBA from Drexel University, where she graduated summa cum laude. The first qualification is an unexpected line on the résumé of an agricultural executive. Ancient civilizations and contemporary crop protection rarely share a conference programme.

The juxtaposition is enjoyable without requiring a grand theory about it. Her professional education continued through the responsibilities she took on. FMC’s account of her advancement records marketing, regulatory and management positions, including Mexico country manager, business director for Professional Solutions and commercial director for Environmental Solutions. This was a career assembled across functions.

She joined FMC in 1996. Twenty years later, in July 2016, its board elected her a vice president after her appointment as business director for North America Crop. Before that appointment, she had been a global director of marketing, strategy and innovation. The progression required her to move between geographical markets and increasingly broad business responsibilities.

A résumé compresses all this into tidy lines. The underlying distinction matters: someone responsible for one function can optimise that function; someone responsible for a business has to reconcile competing needs. Regulatory requirements, customer expectations and commercial plans do not conveniently arrive in the same order. O’Shea’s range of assignments put those different demands inside one career.

Taking the chair, then taking the business

In February 2020, O’Shea joined Certis USA as president. A planned leadership transition followed, and the company announced her move into the CEO role that July. Her predecessor, Jow-Lih Su, moved to an executive board position. The sequence gave her several months inside the business before the handover was completed.

Her account of those months emphasised reviewing the product portfolio, engaging with global operations and building customer relationships. It is a revealing set of priorities for a new leader. Before deciding where a business should go, she was examining what it already sold, how it worked and whom it served.

Certis put manufacturing squarely within her remit, including facilities in the United States and India. Its production history offered a particularly concrete version of the biologicals business. A liquid-fermentation facility in Wasco, California, stood at the centre of its manufacturing story; the company also had a Montana plant and neem-oil production in India.

There is something pleasingly unglamorous about fermentation tanks in a story about innovation. They insist on the physical world. A product needs a process that can produce it, and a business needs the capacity to supply it. O’Shea’s Certis years placed those obligations alongside product development. The management job reached well beyond announcing the next ingredient.

The business behind the bottle

Certis became Certis Biologicals in 2021, marking its twentieth anniversary with a name that made its specialty explicit. O’Shea discussed expansion beyond its established international base, including opportunities in Latin America and Asia. The outward-looking ambition was paired with a product pipeline and existing production capacity.

In 2022, the company and Novozymes announced joint development work for corn and soybeans. Field trials were testing combinations of their technologies. The collaboration moved the discussion into traditional row crops, where the challenge includes fitting a new product into established farming practices. Working together offered a route to developing those combinations.

Another change that year was thoroughly commercial: Certis prepared to sell BotaniGard and Mycotrol directly through its distribution partners after a third-party arrangement ended. The products were already manufactured in its US facilities. The task was to support customers through a change in how they obtained them, with technical staff and distributors carrying part of the load.

By December, Certis had given Mike Allan a business-development and licensing remit to pursue partnerships, licences and potential acquisitions. O’Shea pointed to the combination of laboratory capabilities and market access. The business could contribute more than a research setting to a collaboration. It could help an emerging technology travel towards customers. That combination would recur in her next assignment.

An invention needs instructions

In a 2023 essay, O’Shea described progress in biological products through a cluster of improvements: formulation, manufacturing, targeted application and grower education. This is an unusually serviceable way to discuss a field that can attract large promises. It breaks the problem into tasks people can work on.

Consider the questions implied by that list. Will the product retain its useful properties? Can it be made consistently? Can it be applied where it is needed? Does the person using it understand its place in a crop-management programme? Each question belongs to a different part of the business. A chief executive has to keep them in the same conversation.

Her argument also gave sales and technical support a role in the development of the market. A biological product can be unfamiliar even to an experienced grower. Clear instruction and informed advice help turn unfamiliarity into a decision. An instruction sheet is unlikely to receive applause at an innovation conference. It may still be the thing that gets read.

Here her career in commercial and operational roles meets her interest in biological agriculture. The article’s underlying emphasis is on the work required to improve products and their use. Sustainability arrives with a set of practical conditions. The interesting management challenge is making those conditions hold together, so the environmental ambition has a business capable of carrying it.

A team built for the journey

Invaio paired O’Shea’s appointment with a plan to expand its agricultural technologies, including its precision-delivery work in citrus and an AI platform designing peptides. The programme brought ingredient development and delivery into the same company. Her job placed commercial execution alongside that scientific agenda.

In November 2024, Invaio announced Chris Judd as chief commercial officer and Scott Kantor as chief financial officer. Judd brought experience from BASF, Novozymes and Certis Biologicals. Kantor had most recently served as finance chief at Emulate. O’Shea welcomed the appointments as part of the company’s effort to scale its work.

The two positions make the business question explicit. Commercial leadership concerns the route to the customer. Financial leadership concerns the resources and discipline required to keep travelling. These appointments put names and responsibilities behind an ambition that would otherwise remain easy to describe and difficult to execute.

In May 2025, Magalie Guilhabert joined as chief science officer, following agricultural research leadership at Ginkgo Bioworks and Bayer. Her brief included overseeing research and development and guiding scientific strategy. Together, the appointments show the different forms of expertise involved in O’Shea’s assignment. A company trying to build products needs people who understand both the experiment and the organisation around it.

Three children, and a wider table

In an essay published in January 2026, O’Shea connected raising three children while pursuing her career with lessons in empathy, prioritisation and perseverance. She presented those qualities as useful to leadership in sustainable agriculture. It is a personal explanation of what she brings to the role, grounded in responsibilities beyond her job title.

She also argued for more education, mentorship and opportunity for women across agricultural technology, policy and farm leadership. The scope of that argument matters. It includes people developing products and people using them, and treats leadership as something that should be cultivated across the industry rather than concentrated in a handful of executive positions.

Her direct advice to women has been similarly practical: “it’s OK to learn on the job.” That small permission is consistent with a career that moved through different disciplines. It gives learning a place inside responsibility. Taking a position need not mean that every answer is already neatly filed away.

There is a useful connection between these two strands of her public thinking. Products need supporting systems to make their way into agriculture. People need opportunity and support to move into leadership. Neither journey happens simply because someone has identified potential. Her advocacy puts attention on the conditions under which that potential can become useful work.

“it’s OK to learn on the job.”Amy O’Shea, 2023

More than one route to the field

O’Shea’s board work broadens that view. She joined Gensource Potash’s board in April 2020, attracted by its approach to sustainable production and its proposed business model. The role placed her experience in agricultural markets alongside a company working on a different part of the farm-input supply chain.

Her current Flagship biography also lists board roles at INTAG and Terrana Biosciences. When Flagship unveiled Terrana in July 2025, O’Shea was among its directors, alongside Ignacio Martinez, Hugh Grant and André Andonian. Terrana was developing RNA-based agricultural technologies. Its approach was distinct from Invaio’s, while sharing the task of translating biological ideas into products.

The later public picture remains outward-facing. Invaio listed O’Shea as a panel speaker at the June 2026 World Agri-Tech South America Summit in São Paulo, for a discussion about scaling biological crop protection. Its September announcements listed her planned attendance at industry meetings in London and Dallas. These are occasions for connecting science, business and agricultural markets.

The itinerary is apt. O’Shea’s career has involved moving between countries, functions and organisations, while the underlying question persists: how does an idea become something a customer can rely on? The classical-civilizations degree remains an appealing detail. The more consequential detail is the succession of jobs that followed it. They placed her at the points where a company must make its promises practical, and where a grower gets to decide whether the journey was worth taking.